Schizophrenia Clinical Trials in Fort Lauderdale
View 114 new treatments for Schizophrenia in Fort Lauderdale, FL, and nearby areas, such as Davie, Hollywood, Miramar and Pembroke Pines. Every day, Power helps hundreds of schiz patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Iloperidone Safety for Adolescent Schizophrenia
Vanda Clinic, Miami + 1 more
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Verified
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
RL-007 for Cognitive Impairment in Schizophrenia
Recognify Life Sciences Clinic, Miami Lakes + 5 more
This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More
Verified
Recruiting
Phase 2
Est. 5 - 8 Weeks
Gary Walker, PhD
Study Director
Emraclidine for Schizophrenia
Cerevel Clinic, Hialeah + 4 more
This trial is testing a medication called Emraclidine in people with schizophrenia who are having a worsening of their symptoms. Emraclidine works by targeting brain chemicals to help reduce psychotic episodes.Show More
Verified
Recruiting
Phase 2
Est. 3 - 12 Weeks
Erica Koenig, PhD
Study Director
Medication + Cognitive Training for Schizophrenia
Research Clinic, Miami + 1 more
The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Dante Durand, MD
Principal Investigator
Vortioxetine for Schizophrenia
Research Clinic, Lauderdale Lakes + 1 more
This is a 16-week, randomized, double-blind, parallel group, placebo-controlled study comparing adjunctive vortioxetine with identically appearing adjunctive placebo pills in 88 stable patients with a research diagnosis of schizophrenia determined with the Structured Clinical Interview for DSM (SCID). Patient randomization will be stratified by illness duration (i.e., \</=5 years and \>5 years) in order to allow for post-hoc analyses examining whether earlier illness moderates greater negative and /or cognitive symptom reduction in response to vortioxetine.Show More
Waitlist
Phase 4
Est. 5 - 8 Weeks
Christoph U Correll, MD
Principal Investigator
KarXT for Schizophrenia
Karuna Clinic, Lauderhill + 3 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Ronald Marcus, MD
Study Director
Lumateperone for Schizophrenia and Bipolar Disorder
Intra-Cellular Therapies Clinic, Miami Springs + 2 more
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia or bipolar disorder.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Miami + 5 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Brilaroxazine for Schizophrenia
Reviva Clinic, Hollywood + 2 more
This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Medical Director
Study Director
SEP-363856 for Schizophrenia
Sunovion Clinic, Miami + 4 more
This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
CNS Medical Director
Study Chair
Page 1 of 3
Frequently Asked Questions
Explore related conditions